| 臺大學術典藏 |
2022-09-15T01:09:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Chia-Chi Lin |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Chia-Chi Lin; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:43Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Chia-Chi Lin; Chen Y.-J.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-14T01:29:23Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-13T08:19:08Z |
TSOC-HFrEF registry: A registry of hospitalized patients with decompensated systolic heart failure: Description of population and management
|
Wang C.-C.; Chang H.-Y.; Yin W.-H.; Wu Y.-W.; Chu P.-H.; CHIH-CHENG WU; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Lin W.-S.; Huang J.-L.; Chen S.-M.; Yang N.-I.; Chang H.-C.; Chang K.-C.; Sung S.-H.; Shyu K.-G.; Lin J.-L.; Mar G.-Y.; Chan K.-C.; Kuo J.-Y.; Wang J.-H.; Chen Z.-C.; Tseng W.-K.; Cherng W.-J. |
| 臺大學術典藏 |
2022-09-13T08:19:07Z |
The Obesity-Mortality Paradox in Patients With Heart Failure in Taiwan and a Collaborative Meta-Analysis for East Asian Patients
|
Lin G.-M.; Li Y.-H.; Yin W.-H.; Wu Y.-W.; Chu P.-H.; CHIH-CHENG WU; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Wang C.-C.; Yeh S.-J.; Lin W.-S.; Chan K.-C.; Chang H.-C.; Chang K.-C.; Chen Z.-C.; Chen S.-M.; Chu P.-H.; Hsu C.-H.; Huang J.-L.; Kuo J.Y.; Lin J.-L.; Lin W.-S.; Mar G.-Y.; Shyu K.-G.; Sung S.-H.; Tseng W.-K.; Voon W.-C.; Wang J.-H.; Wen M.-S.; Yang N.-I. |
| 臺大學術典藏 |
2022-09-13T08:19:05Z |
One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFreF registry
|
Chang H.-Y.; Wang C.-C.; Wu Y.-W.; Chu P.-H.; CHIH-CHENG WU; Hsu C.-H.; Wen M.-S.; Voon W.-C.; Lin W.-S.; Huang J.-L.; Chen S.-M.; Yang N.-I.; Chang H.-C.; Chang K.-C.; Sung S.-H.; Shyu K.-G.; Lin J.-L.; Mar G.-Y.; Chan K.-C.; Kuo J.-Y.; Wang J.-H.; Chen Z.-C.; Tseng W.-K.; Cherng W.-J.; Yin W.-H. |
| 臺大學術典藏 |
2022-09-07T06:50:50Z |
Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan
|
Tu C.-H.; Lee C.-T.; Perng D.-S.; Chang C.-C.; Hsu C.-H.; YI-CHIA LEE |
| 臺大學術典藏 |
2022-09-06T08:56:53Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2022-09-06T07:43:16Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; MING-SHIANG WU; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-06T02:41:54Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Lam C.S.P.; Hung C.-L.; Liew H.B.; Narasimhan C.; Ngarmukos T.; Park S.W.; Reyes E.; Siswanto B.B.; Shimizu W.; Zhang S.; Fan X.; Chen K.; Wu L.; Xie Y.; Jin Q.; Ling T.; Li X.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Yu C.M.; Sastry B.K.S.; Gopi A.; Raghu K.; Sridevi C.; Kaur D.; Naik A.; Parikh K.; Chandarana A.; Shah U.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Tandon R.; Chopra V.; Kumar M.; Sethi H.J.S.; Verma R.; Mittal S.; Sawhney J.; Sharma M.K.; Purayil M.P.; Tedjokusumo P.; Martanto E.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Danny S.S.; Surarso R.; Noda T.; Nakajima I.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Kabuki T.; Kiuchi S.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Park S.-M.; Roh S.-Y.; Kim Y.H.; Kim M.; Choi J.-I.; Na J.O.; Rha S.W.; Seo H.S.; Oh D.J.; Park C.G.; Kim E.J.; Joung B.; Uhm J.-S.; Lee M.H.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Saharudin S.; Beh B.C.; Lee Y.W.; Yen C.H.; Othman M.K.; Augustine A.-A.; Asnawi M.H.M.; Mojolou R.A.; Tan Y.Z.; Arbain A.N.; Wong C.K.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Azmee M.G.; Abidin I.Z.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Amin N.H.M.; Seng K.C.; Tan S.K.; Yew K.L.; Santos J.; Lim A.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Tan B.Y.; Lim C.P.; Teo L.L.Y.; Chan L.L.H.; Chai P.; Wong C.C.R.; Poh K.K.; Yeo P.S.D.; Lee E.M.; Loh S.Y.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Jaufeerally F.R.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Chien K.-L.; Su T.-C.; LIAN-YU LIN; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Hung C.-S.; Chang S.-N.; Lin J.-W.; Hsu C.-N.; Yu W.-C.; Chao T.-F.; Sung S.-H.; Wang K.-L.; Leu H.-B.; Lin Y.-J.; Chang S.-L.; Huang P.-H.; Lo L.-W.; Wu C.-H.; Liang H.-Y.; Chang S.-S.; Hsiao L.-C.; Wang Y.-C.; Lu C.-R.; Wu H.-P.; Lin Y.-N.; Chen K.-W.; Lo P.-H.; Hsu C.-H.; Hsieh L.-C.; Chandavimol M.; Yingchoncharoen T.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators |
| 臺大學術典藏 |
2022-09-02T02:56:45Z |
A randomized controlled trial of clinic-based and home-based interventions in comparison with usual care for preterm infants: Effects and mediators
|
Jeng S.-F.; Wu Y.-T.; Chen L.-C.; Yu Y.-T.; Li-Jung Fang, Hsu H.-C.; Yang M.-C.; Chiu N.-C.; Chen W.J.; SUSAN SHUR-FEN GAU; Wu Y.-C.; Leng C.-H.; Hsieh W.-S.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Hsu C.-H.; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N.; Chao Y.; Chen J.-S.; Bang Y.-J.; Bendell J.; Lee K.-H.; Wang Y.; Abdullah H.; Liu B.; Spahn J.; Hack S.P.; Verret W.; CHIH-HUNG HSU; Lee M.S. |
| 臺大學術典藏 |
2022-08-19T00:21:17Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Yeh K.-H.; Bu C.-F.; Lin C.-C.; Lu Y.-S.; Yang C.-H.; CHIUN HSU; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:15Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.; Wu C.-Y.; Chen J.-S.; Li C.-C.; Liu H.-T.; Hsu C.-H.; Lu Y.-S.; Yeh K.-H.; Yang C.-H.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:12Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; Cheng A.-L.; CHIUN HSU; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:21:10Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; CHIUN HSU; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:09Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; CHIUN HSU; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:08Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; CHIUN HSU; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; CHIUN HSU; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:01Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
